Characterisation of the thermal, spectroscopic and drug dissolution properties of mefenamic acid and polyoxyethylene-polyoxypropylene solid dispersions

Journal of Pharmaceutical Sciences

Volumn 98, Issue 12, 2009, Pages 4545-4556

  Andrews, Gavin P ^a   Zhai, Hui ^a   Simon, Tipping ^a   Jones, David S ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Hyper DSC; Lutrol F68 ; Mefenamic acid; Raman spectroscopy; Solid dispersions

Indexed keywords

BUFFER; MEFENAMIC ACID; PHOSPHATE; POLOXAMER;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG SOLUBILITY; FLUORESCENCE MICROSCOPY; MISCIBILITY; PH; RAMAN SPECTROMETRY; SPECTROSCOPY; X RAY POWDER DIFFRACTION;

EID: 71649096923     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21752     Document Type: Article

References (37)

1. McNamara DP, Childs SL, Giordano J, Larriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility drug. Pharm Res 23:1888-1897. (Pubitemid 44200553)
2. Miller DA, McConville JT, Yang W, Williams RO, McGinityJW. 2007.Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci 96:361-376.
3. Reverchon E. 1999. Supercritical antisolvent precipitation of micro- and nano-particles. J Supercrit Fluids 15:1-21. (Pubitemid 129671809)
4. Janssens S, De Armas HN, Roberts CJ, Van Den Mooter G. 2008. Characterisation of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci 97:2110-2120.
5. Dong ZD, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. 2008. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm 355:141-149.
6. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47-60. (Pubitemid 30326688)
7. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
8. Zheng X, Yang R, Tang X, Zheng LY. 2007. Part I: Characterisation of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev Ind Pharm 33:791-802. (Pubitemid 47123802)
9. Moneghini M, Bellich B, Baxa P, Princivalle F. 2008. Microwave generated solid dispersions containing ibuprofen. Int J Pharm 361:125-130.
10. Zhu YC, Shah NH, Malick AW, Infeld MH, McGinity JW. 2006. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Drug Dev Ind Pharm 32:569-583.
11. Shibata Y, Fujii M, Kokudai M, Noda S, Okada H, Kondoh M, Watanabe Y. 2007. Effect of characteristics of compounds on maintenance of an amorphous state in solid dispersion with crospovidone. J Pham Sci 96:1537-1547. (Pubitemid 46953769)
12. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231:131-144.
13. Chokshi RJ, Shah NH, Harpreet K, Sandhu AW, Malick HZ, Zia H. 2008. Stabilization of low glass transition temperature indomethacin formulations: Impact of polymer-type and its concentration. J Pharm Sci 97:2286-2292.
14. Suryanarayanan R, Venkatesh S, Hodgin L, Hanson P. 1992. Determination of the physical state of salicylic acid in hydrogel formulations by X-ray diffractometry. Int J Pharm 78:77-83.
15. Alexander LE, Klug HP. 1974. X-ray diffraction procedures for polycrystalline and amorphous materials. New York: Wiley.
16. Fini A, Moyano JR, Ginés JM, Perez-Martinez JL, Rabasco AM. 2005. Diclofenac salts, II. Solid dispersions in PEG6000 and Gelucire 50/13. Eur J Pharm Biopharm 60:99-111. (Pubitemid 40545866)
17. Jenquin MR, McGinity JW. 1994. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interaction. Int J Pharm 101:23-34. (Pubitemid 24028526)
18. Matsumoto T, Zografi G. 1999. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidoneco-vinylacetate) in relation to indomethacin crystallization. Pharm Res 16:1722-1728. (Pubitemid 29530405)
19. Ford JL, Stewart AF, Dubois J-L. 1986. The properties of solid dispersions of indomethacin or phenylbutazone in polyethylene glycol. Int J Pharm 28:11-22.
20. Qi S, Gryczke A, Belton P, Craig DQM. 2008. Characterisation of solid dispersions of paracetamol and Eudragit (R) E prepared by hot-melt extrusion using thermal, microthermal and spectroscopic analysis. Int J Pharm 354:158-167.
21. Yazdanian M, Briggs K, Jankovsky C, Hawi A. 2004. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 21:293-299.
22. Schmidt PC, Adam A, Schrimpl L. 2000. Factors influencing capping and cracking of mefenamic acid tablets. Drug Dev Ind Pharm 26:489-497. (Pubitemid 30225626)
23. Wei L, Li J, Guo L, Nie S, Pan W, Sun P, Liu H. 2007. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol. Drug Dev Ind Pharm 33:990-998. (Pubitemid 47463810)
24. Ramesh P, Prakash S, Omathanu P, Shrutidevi A, Yasvanth AR. 2004. Solid-state characterisation of mefenamic acid. J Pharm Sci 93:1019-1029.
25. Haleblian JK, McCrown W. 1969. Pharmaceutical applications of polymorphism. J Pharm Sci 59:911-929.
26. Cowie JMG. 1991. Polymers: Chemistry & physics of modern materials. 2nd edition. New York: Chapman & Hall. pp 241-243.
27. Yin SX, Franchini M, Chen J, Hsieh A, Jen S, Lee T, Hussain M, Smith R. 2005. Bioavailability enhancement of a COX-2 inhibitor, BMS-347070, from a nanocrystalline dispersion prepared by spray-drying. J Pharm Sci 94:1598-1607. (Pubitemid 41168688)
28. Qian F, Tao J, Desikan S, Hussain M, Smith RL. 2007. Mechanistic investigation of Pluronic® based nano-crystalline drug-polymer solid dispersions. Phamr Res 24:1551-1560. (Pubitemid 46988222)
29. Umeda T, Ohnishi N, Yokoyama T, Kuroda T, Kita Y, Kuroda K, Tatsumi E, Matsuda Y. 1985. A kinetic study on the isothermal transition of polymorphic forms of tolbutamide and mefenamic acid in the solid state at high temperatures. Chem Pharm Bull 83:2073-2078. (Pubitemid 15004722)
30. Yilgocombining double acute accentr E, Yurtsever E, Yilgocombining double acute accentr I. 2002. Hydrogen bonding and polyurethane morphology II. Spectroscopic, thermal and crystallization behavior of polyether blends with 1,3-dimethylurea and a model urethane compound. Polymer 43:6561-6568.
31. Theeuwes F, Hussain A, Higuchi T. 1974. Quantitative analytical method for determination of drugs dispersed in polymers using differential scanning calorimetry. J Pham Sci 63:427-429.
32. Gramaglia D, Conway BR, Kett VL, Malcolm RK, Batchelor HK. 2005. High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. Int J Pharm 301:1-5. (Pubitemid 41206584)
33. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698. (Pubitemid 28062912)
34. Gilpin RK, Zhou W. 2005. Infrared studies of the thermal conversion of mefenamic acid between polymorphic states. Vib Spectrosc 37:53-59. (Pubitemid 40072584)
35. Dhanaraj V, Vijayan M. 1988. Structural studies of analgesics and their interactions: Structure and interactions of anti-inflammatory fenamates - A concerted crystallographic and theoretical conformational study. Acta Crystallogr 44:406-412.
36. Aguiar AJ, Zelmer JE. 1969. Dissolution behavior of polymorphs of chloramphenicol palmitate and metenamic acid. J Pharm Sci 58:983-987.
37. Portero A, Remunan-Lopez C, Vila-Jato JL. 1998. Effect of chitosan and chitosan glutamate enhancing the dissolution properties of the poorly water soluble drug nifedipine. Int J Pharm 175:75-84. (Pubitemid 28487017)